Background To provide a global profile of supplemental ultrasonography (US)
Results Twenty-three studies were included, including 12 supplemental US screening studies and 11 joint screening studies in which both MAM and US were used as primary screening methods. Meta-analyses revealed that supplemental US screening could detect 96% [95% confidential intervals (CIs): 82% to 99%] of occult breast cancers missed by MAM and identify 94% (95% CIs: 88% to 97%) of healthy women, with a CDR of 2.9/1000 (95%CIs: 1.8/1000 to 3.9/1000), RR of 8.6%
(95%CIs: 4.8% to 13.5%), BR of 3.9% (95%CIs: 2.5% to 5.5%), ProICof 73.9% (95%CIs: 49.0% to 93.7%), and ProNPC of 72.6% (95%CIs: 51.9% to 90.0%).
Compared with primary MAM screening, primary US screening led to the recall of significantly more women with positive screening results [1.2% (95%CIs:0.4% to 1.9%), P =0.004] and detected significantly more invasive cancers [20.2% (95%CIs: 7.2% to 33.1%), P = 0.002]. However, there were no significant differences for other performance measures between the two screening methods, including sensitivity, specificity, CDR, BR, and ProNPC.
Conclusions Supplemental US screening could detect occult breast cancers missed by MAM, while primary US screening performances are comparable to those of primary MAM screening, but with a higher recall rate and a higher detection rate for invasive cancers.
Background
Cancer is a global public health issue in the world. In 2016, an estimated 17.2 million cancer cases and 8.9 million cancer deaths occurred worldwide [1] . For women, both the most commonly occuring cancer and the leading cause of cancer deaths and disability-adjusted life-years (DALYs) was breast cancer (1.7 million incident cases, 535, 000 deaths, and 14.9 million DALYs) [1] . Over the years, the burden of cancer has shifted from more developed countries to less developed countries [2] . Moreover, the burden is expected to grow worldwide due to the aging of the population and the adoption of lifestyle behaviors such as smoking, poor diet, physical inactivity, and reproductive changes (including lower parity and later age at first birth), particularly in less developed countries [2] . Therefore, broad prevention measures, such as cancer screening, are urgently needed to control this increasing burden, especially in less developed countries.
Mammography (MAM) has been used to screen for breast cancer since the 1970s and is now widely available in developed countries. However, in less developed counties, such as China, MAM is not easily accessible due to several barriers, including insufficient MAM equipment, inadequate insurance coverage for MAM, and widely dispersed populations [3] . Moreover, MAM has a low sensitivity in women with dense breasts [4] , who could suffer a higher risk of breast cancer than those without dense breasts [5] . Worrisome research from Denmark and Netherlands showed that nearly one in every three or half of screening-detected breast cancers represents overdiagnosis, respectively [6, 7] .
Recent data indicates that supplemental ultrasonography (US) screening could detect occult breast cancers missed by MAM, and primary US screening seems perform comparably to primary MAM screening [8] [9] [10] [11] . However, systematic reviews of the performances of supplemental or primary US screening have been published only in limited studies. Moreover, among broad screening studies in which both MAM and US were used as primary screening methods, researchers just focused on the performance differences between joint screening and MAM screening alone. Limited studies investigated the independent performances of primary US screening.
Therefore, we conducted this systematic review and meta-analysis to provide a global profile of supplemental US screening after MAM screening or primary US screening for breast cancers.
Materials and Methods
This meta-analysis was reported in line with the preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: The PRISMA-DTA Statement (Supplementary S1) [12].
Types of studies and participants
Randomized-controlled trials (RCTs), prospective or retrospective screening cohort studies reporting any of the following performance values for supplemental or primary US screening were included: sensitivity, specificity, cancer detected rate (CDR), recall rate (RR), biopsy rate (BR), and proportions of invasive cancers (ProIC) or node-positive cancers (ProNPC) among screening-detected cancers. The types of US included were hand-held ultrasonography (HHUS) and automated whole breast ultrasonography (ABUS). Diagnostic studies of patients with histopathologically proven breast cancer or women with suspicious finding after initial screening were excluded. Screening studies for second cancers among women previously diagnosed with breast cancer were also excluded. 
Searching strategies

Selection of studies
Two authors independently screened the titles and abstracts of all selected articles to confirm their eligibility. All selected articles were analyzed by EndNote software that allows reviewers to manage articles and detect duplicate publications. When two or more articles from the same trial were selected, the article with the larger sample size, longer duration of follow-up, or the latest results was included. Any disagreement on the selection of articles was discussed and arbitrated by a third author. Details of the selection process are provided in the supplementary S3.
Data extraction
Two authors independently extracted the following data from the qualifying studies: general information (name of first author, year of publication, and country or countries where the study was performed), design of study (sample size, mean age, percent of women with dense breasts among the whole population, type of US, screening mode), performance of US, and information for risk assessment of bias (detailed information referred to in the following section). All data was entered into STATA 14.0 software for analysis. Any disagreements on data extracted were also discussed and arbitrated by the same third author.
Risk assessment of bias in included studies
Two investigators critically appraised all included studies independently according to the pre-specified criteria, which were adjusted from the USPSTF's design-specific criteria and the STARD checklist for reporting diagnostic accuracy studies [14, 15] .
The adjusted criteria included: (1) Included population came from a representative source population (Yes: general community women or well-defined high-risk women;
No: women participants in an opportunistic screening and other undefined women)
(2) Sample size was greater than or equal to 1000 (Yes/No) (3) Included studies clearly described the inclusion and exclusion criteria, and women who had a personal history of breast cancer were definitely excluded before screening (Yes/No) (4) In studies in which more than one screening method was used as the primary screening method, the readers of different screening methods were masked to each other (Yes/No) (5) All participants received US screening, or the proportion of missing data for either test was less than or equal to 5% (Yes/No) (6) US findings were interpreted according to BI-RADS criteria (Yes/No) (7) Women with positive results from index screening methods were ascertained with histopathology; and women with negative results were ascertained with a minimum 12-month clinical follow-up (reference standards) (Yes/No).
According to the above mentioned criteria, high-quality studies were defined as those meeting at least six criteria for joint screening studies and five criteria for supplemental US screening studies. Fair-quality studies meet four or five criteria for joint screening studies and three or four criteria for supplemental US screening studies. Poor quality studies were defined as those meeting less than four criteria for joint screening studies and three criteria for supplemental US screening studies.
Poor studies were excluded from the review.
Data synthesis and analysis
All data were extracted with pre-specified uniform tables and recalculated with uniform methods.The corresponding authors will be contacted to obtain any missing information from their studies. The recall rate was calculated as the number of women recalled for further diagnosed examinations divided by the total number of women participated the screening. If the number of women recalled for any further diagnosed examinations was not available, the number of women with a positive result of index screening modality was used instead. The biopsy rate was calculated as the number of women recalled for pathological examination divided by the total number of women participated the screening.
The variation in different screening performances attributable to heterogeneity was measured as I 2 . If the P value for I 2 was less than 0.1, significant heterogeneity was indicated among included trials and the random-effect model was used to combine screening performances [16] . Otherwise, the fixed-effect model was used if the P value for I 2 was larger than 0.1. To search for sources of heterogeneity and obtain clinically meaningful estimates, subgroup analyses were conducted according to different studies characteristics, such as sample size > 1000 (Yes/No), all women with dense breasts (Yes/No), type of US (HHUS/ABUS), and quality assessment (Yes/No), whenever possible. The package "midas" was used to combine sensitivity and specificity, to investigate whether there were potential publication biases among included studies, and to plot the summary receiver operating characteristic (SROC) curve with its 95% confidence and prediction contours [17]. The package "metaprop" was used to combine CDR, RR, BR, ProIC, and ProNPC [18] . In addition, the package "metan" was used to compare the performances between MAM and US [19] .
All meta-analyses were conducted with STATA software (version 14.0). All tests were two-sided, and P values of less than 0.05 for all meta-analyses indicated statistical significance.
Results
Supplementary figure S3 shows a flowchart of the study selection procedure. The electronic searches yielded 1162 potentially relevant studies, of which 23 eligible studies were included in the final review [9-11, 20-39], including 12 supplemental US screening studies and 11 joint screening studies in which both MAM and US were used as primary screening methods. Table 1 shows the baseline characteristics of the 23 studies. Twelve studies were conducted among women with dense breasts. Twenty studies screened women with HHUS. Twelve studies were conducted among general community women or welldefined high-risk women. Eleven studies definitely excluded women who had a personal history of breast cancer. Eight joint screening studies masked the results of primary MAM screening and primary US screening. Nineteen studies had low risk of incomplete data. Sixteen studies reported US results according to BI-RADS classification criteria. The reference standard in seventeen studies was pathologic examination combined with 12-month clinical follow-up. Finally, according to the pre-specified criteria, seven studies were of good quality, while the left 16 were of fair quality. Table 2 shows the original data of screening accuracy for supplemental and primary US screening among the included studies. Based on meta-analyses, supplemental US screening could detect 96% [95% confidential intervals (CIs): 82% to 99%; I 2 = 66.3%, P < 0.01] of occult breast cancers missed by MAM and identify 94% (95% CIs: 88% to 97%; I 2 = 99.8%, P < 0.01) of healthy women ( Figure 1A , supplementary S4). The area under the SROC (AUC) for supplemental US screening was 99% (95CIs: 97% to 99%) ( Figure 1A ). No publication bias was found among these studies (P = 0.465).
Screening accuracy for supplemental and primary US screening
Among 11 joint screening studies, primary MAM screening could detect 64% (95%CIs: 53% to 74%; I 2 = 93.5%, P < 0.01) of breast cancers and identify 97% (95% CIs: 94% to 99%; I 2 = 99.9%, P < 0.01) of healthy women ( Figure 1B , supplementary S5), respectively. Primary US screening could detect 55% (95%CIs: 37% to 71%; I 2 = 95.5%, P < 0.01) of breast cancers and identify 98% (95CIs: 94% to 99%; I 2 = 100%, P < 0.01) of healthy women ( Figure 1C , supplementary S6). The AUCs for primary MAM screening and primary US screening were 88% (95CIs: 85% to 91%) ( Figure 1B ) and 90% (95CIs: 87% to 93%) ( Figure 1C ), respectively. No publication bias was found for both primary MAM screening (P = 0.209) and primary US screening (P = 0.466). No significant differences were found for either sensitivity [-10 .9% (95%CIs: -29.0% to 7.2%), P = 0.239; I 2 = 91.8%, P < 0.001] or specificity [-0.2% (95%CIs: -0.9% to 0.4%), P = 0.510; I 2 = 96.7%, P < 0.001] between primary MAM screening and primary US screening ( Figure 2 ). Table 3 shows the original data for screening accuracy for supplemental and primary US screening reported by the included studies. Meta-analyses determined that the summary CDR for supplemental US screening was 2.9/1000 (95%CIs: 1.7/1000 to 4.5/1000; I 2 = 85.2%, P < 0.001), with a RR of 8.6% (95%CIs: 4.8% to 13.5%; I 2 = 99.7%, P < 0.001) and a BR of 3.9% (95%CIs: 2.5% to 5.5%; I 2 = 98.4%, P < 0.001) ( Figure 3 ).
Screening efficacy for supplemental and primary US screening
The summary CDRs for primary MAM screening and primary US screening were 4.5/1000 (95%CIs: 3.1/1000 to 6.0/1000; I 2 = 89.6%, P < 0.001) and 3.7/1000 (95%CIs: 2.4/1000 to 5.2/1000; I 2 = 91.0%, P < 0.001), with summary RRs of 4.1% (95%CIs: 2.0% to 7.0%; I 2 = 99.8%, P < 0.001) and 5.3% (95%CIs: 2.5% to 9.2%; I 2 = 99.8%, P < 0.001), and summary BRs of 1.4% (95%CIs: 0.4% to 2.9%; I 2 = 99.0%, P < 0.001) and 1.9% (95%CIs: 0.8% to 3.4%; I 2 = 98.7%, P < 0.001) ( Figure 4 ).
Compared to primary MAM screening, primary US screening recalled significantly more women with positive screening results [1.2% (95%CIs: 0.4% to 1.9%), P = 0.004] (Figure 2 , -1.2%, 95% CIs (-1.9% to -0.4%), P = 0.003; I 2 = 96.6%, P < 0.001). No significant differences were found for either CDR [-0.6/1000 (95%CIs:-1.7/1000 to 0.6/1000, P = 0.334; I 2 = 73.8%, P < 0.001] or BR [0.6% (95%CIs: -0.1% to 1.2%), P = 0.091; I 2 = 92.2%, P < 0.001] between primary US screening and primary MAM screening ( Figure 2 ). Cancer characteristics for supplemental and primary US screening Table 4 shows the original data for cancer characteristics for supplemental and primary US screening reported by the included studies.After meta-analyses, 73.9% (95%CIs: 49.0% to 93.7%; I 2 = 66.4%, P = 0.007) of cancers detected by supplemental US screening were invasive cancers, while 72.6% (95%CIs: 51.9% to 90.0%; I 2 = 0.0%, P = 0.499) of cancers were node-positive cancers ( Figure 3 ).
Among 11 joint screening studies, 57.1% (95%CIs: 39.8% to 73.6%; I 2 = 88.6%, P < 0.001) and 85.0% (95%CIs: 54.1% to 100.0%; I 2 = 96.2%, P < 0.001) of cancers detected by supplemental US screening and primary MAM screening were invasive cancers, while 58.0% (95%CIs: 28.0% to 85.5%; I 2 = 94.4%, P < 0.001) and 64.1% (95%CIs: 37.8% to 87.3%; I 2 = 91.1 %, P < 0.001) of cancers were node-positive cancers ( Figure 4 ). Compared to primary MAM screening, primary US screening detected significantly more invasive cancers [20.2%, 95% CIs (7.2% to 33.1%), P = 0.002; I 2 = 74.2%, P < 0.001] but a similar number of node-positive cancers [-2.0%, 95% CIs (-13.5% to 9.4%), P = 0.729; I 2 = 57.6%, P = 0.028] (Figure 2 ).
Subgroup analyses
Subgroup analyses showed very similar results to those of primary analyses (Supplementary S7 and S8). In addition to results comparable to those observed in the primary analyses, lower sensitivity, higher specificity, and higher cancer detection rate were found for supplemental US screening among women with dense breasts compared to those without dense breasts (Supplementary S7). Moreover, the differences for sensitivities, specificities, and cancer detection rates between primary MAM screening and primary US screening were smaller among women with dense breasts compared to those without dense breasts (Supplementary S8). However, this review did not investigate the performance of primary US screening.
Discussion
Our studyis the first systematic review and meta-analysis to investigate the performance of primary US screening for breast cancer, and this is also an important up-to-date systematic review and meta-analysis investigating the performance of supplemental US screening. Several reasons would lead to these inconsistent recommendations among current guidelines. As argued by USPSTF, sparse good evidence would be the major reason.
However, as shown in our study, several high-quality studies and fair-quality studies had been conducted since 2003. Although EUSOBI supported supplemental US screening after MAM, it also addressed the concern that breast US was inappropriately suggested to be a primary screening method since primary US screening had not been shown to reduce mortality of breast cancer in the general female population. Moreover, US would lead to more biopsies and recalls than MAM [44] . In this systematic review, we did observe higher recall rates for US compared to MAM. We also observed higher biopsy rates for US compared to MAM; however, the difference was nonsignificant. This nonsignificant difference in biopsy rates between US and MAM may be due to small sample sizes, but it may also reflect no actual difference. In addition, there are several limitations of breast ultrasound that would make it inappropriate for a screening test. These include:US cannot take an image of the whole breast at once as MAM does; US cannot show microcalcifications, which would be the most common feature of tissue around a tumor; the skill level of the US operators makes a great difference in the screening results. However, as shown in our study, these concerns seemed not to cause significant differences in the sensitivity and specificity, or even in cancer detection rates and cancer characteristics (such as the proportion of node-positive cancers) between primary US screening and primary MAM screening. Moreover, lower price, larger coverage, absence of radiation effects, and lower overdiagnosis rates for US compared to MAM make US more easily accepted in China and other countries [3, 49, 50].Therefore, CACA and other societies supported supplemental US screening in their guidelines.
Lastly, the following results are significant. First, we observed significantly higher RR and ProIC for primary US screening compared with primary MAM screening.
Higher recall rates would be an important barrier to promote US screening. More studies are needed to investigate the factors influencing false positive caused by US screening so as to reduce unnecessary recalls. In contrast to the higher rate of detection of microcalcified cancers by MAM, detection of more invasive cancers by US would be another potential advantage compared to MAM, since we usually cannot classify invasive cancers as overdiagnosed cancers. Second, we did not observe obvious differences in the performance of supplemental US screening between women with and without dense breasts. These results further support the position that the performance of supplemental US screening would not be easily influenced by dense breasts. However, we also did not observe significantly higher sensitivity for US compared to MAM among women with dense breasts. Small sample size could be an important factor, since only three of 11 included studies recruited women with dense breasts.
Limitations
First, due to lack of evidence for reduced mortality from breast cancer, we cannot conclude that US screening would lead to a long-term benefit. Second, in addition to breast density, no studies investigated whether other risk factors (such as obesity) influenced the differences in screening performance between US and MAM. Therefore, we cannot conclude whether these different performances between US and MAM derived from confounding effects or from the actual differences between US and MAM. Third, missing data in several important performance indexes, such as recall rate and biopsy rate, could lead to biased results. Uniform reporting guidelines for US or MAM screening studies are needed to improve comparability between different studies. 
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